Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Complementary roles of liquid biopsy and imaging in metastatic cancer

Sabine Mouawad, MD, Gustave Roussy, Villejuif, France, explores a retrospective analysis of patients with metastatic cancer examining whether CT-derived tumor burden metrics complement liquid biopsy by identifying factors associated with undetectable circulating tumor DNA (ctDNA). Undetectable ctDNA was common and independently associated with lower total tumor volume, fewer lesions, and fewer metastatic sites, with organ-specific differences seen in liver, bone, and lymph node, but not lung, involvement. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

In our study, we tried to understand why we have some patients who have a negative liquid biopsy but still have visible metastatic disease on imaging. To do that, we did a retrospective analysis of 1019 patients who had both liquid biopsy and CT scans at baseline. And we derived imaging metrics from these patients, which were the total tumor volume, the lesion count, and the tumor volume metastatic distribution by organ...

In our study, we tried to understand why we have some patients who have a negative liquid biopsy but still have visible metastatic disease on imaging. To do that, we did a retrospective analysis of 1019 patients who had both liquid biopsy and CT scans at baseline. And we derived imaging metrics from these patients, which were the total tumor volume, the lesion count, and the tumor volume metastatic distribution by organ. So what is interesting in our study is that we found almost 29% of patients who had a negative liquid biopsy while having active metastatic disease on imaging. And we annotated 55,000 metastatic lesions, and we found that these variables, the total tumor volume, the lesion count, and the metastatic locations, which were the liver, the lymph nodes, and the bones, were positively associated with ctDNA detectability independently of each other.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.